Figure 1.

Subconjunctival ssAAV2-STC-1-FLAG lowers IOP in a sustained fashion. A, C57BL/6J mice (n = 8) were injected subconjunctivally with ssAAV2-STC-1-FLAG (2μL; 6 × 10⁹ VG) in 1 eye and ssAAV2-GFP (2μL; 6 × 10⁹ VG) in the fellow eye. Significant, sustained IOP lowering was seen in the eye injected with ssAAV2-STC-1-FLAG. At the end of experimental week 13 when IOP reduction waned, all surviving mice (n = 6) received a second injection. Eyes injected with a second dose of ssAAV2-STC-1-FLAG showed a restored, significant, and sustained IOP reduction until experiment was ended. B, No difference in angle anatomy was seen between mice injected with ssAAV2-STC-1-FLAG and PBS-injected controls. Iris, ciliary body and peripheral retina, and lens. C, Eyes injected with ssAAV2-STC-1-FLAG showed transgene expression at week 1 and month 1 postinjection while no expression was seen in any control eyes whether untreated, PBS-treated, or ssAAV2-GFP-treated. CB = ciliary body; GFP = green fluorescent protein; I = iris; IOP = intraocular pressure; L = lens; PBS = phosphate-buffered saline; R = retina; ssAAV2-STC-1-FLAG = single-stranded, adeno-associated virus, serotype 2, engineered to express stanniocalcin-1 with a FLAG tag; VG = viral genome.